Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Enrique Ocio: myeloma novel targets

Enrique Ocio • 13 Sep 2019
IMW 2019
Multiple Myeloma Avadomide Bortezomib Dexamethasone Melflufen

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, outlines a discussion that took place at the International Myeloma Workshop (IMW) 2019, held in Boston, MA, on novel therapeutic targets and agents for the treatment of multiple myeloma.

More from Enrique Ocio

Isa-VRd in older patients with/without frailty criteria: pooled analysis in newly diagnosed myeloma
3:08
Isa-VRd in older patients with/without frailty criteria: pooled analysis in newly diagnosed myeloma
Enrique Ocio • 6 Dec 2025
The possibility of integrating CELMoDs, CAR T-cells & bispecifics into first-line therapy in myeloma
1:28
The possibility of integrating CELMoDs, CAR T-cells & bispecifics into first-line therapy in myeloma
Enrique Ocio • 8 Dec 2024
Unmet needs in multiple myeloma: patients who are refractory to T-cell engagers and CAR-Ts
1:08
Unmet needs in multiple myeloma: patients who are refractory to T-cell engagers and CAR-Ts
Enrique Ocio • 8 Dec 2024
A pilot study investigating a shorter duration of isatuximab infusion in patients with myeloma
1:16
A pilot study investigating a shorter duration of isatuximab infusion in patients with myeloma
Enrique Ocio • 8 Dec 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Enrique Ocio • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Enrique Ocio • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Enrique Ocio • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Enrique Ocio • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals